Rezolute Book Value 2011-2025 | RZLT

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Rezolute

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
162 M	121 M	116 M	149 M	26.1 M	7.36 M	1.75 M	-3.96 M	8.53 M	8.77 M	9.05 M	6.41 M	-4.16 M	-5.41 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
162 M	-4.16 M	43.5 M

Quarterly Book Value Rezolute

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
147 M	162 M	82.6 M	99.6 M	113 M	121 M	70.9 M	91.7 M	104 M	116 M	127 M	141 M	153 M	149 M	51.9 M	62.3 M	21.6 M	26.1 M	26.1 M	35.9 M	4.38 M	7.36 M	7.36 M	14.7 M	20.6 M	1.75 M	1.75 M	-9.79 M	-6.44 M	-3.96 M	-3.96 M	3.8 M	7.81 M	8.53 M	8.53 M	7.93 M	8.2 M	8.77 M	8.77 M	5.58 M	6.76 M	9.05 M	9.05 M	7.82 M	5.02 M	6.41 M	6.41 M	2.15 M	864 K	-4.16 M	1.1 M	-	480	-1.29 M	8.89 K	-891 K	23.5 K	15.8 K	23.5 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
162 M	-9.79 M	35.4 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
AbbVie ABBV	135 B	$ 223.01	-0.99 %	$ 395 B	USA
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Arbutus Biopharma Corporation ABUS	106 M	$ 4.68	1.85 %	$ 777 M	Canada
Aclaris Therapeutics ACRS	156 M	$ 3.38	3.21 %	$ 261 M	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	39.5 M	-	-15.15 %	$ 60.3 M	Britain
Aeglea BioTherapeutics AGLE	518 M	-	-	$ 1.01 B	USA
Ascendis Pharma A/S ASND	-106 M	$ 212.3	5.5 %	$ 5 B	Danmark
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
BioVie BIVI	19 M	$ 1.54	-2.53 %	$ 2.28 M	USA
Albireo Pharma ALBO	176 M	-	-0.23 %	$ 916 M	USA
Aptorum Group Limited APM	11.8 M	$ 1.33	-1.48 %	$ 7.25 M	China
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
Alterity Therapeutics Limited ATHE	35.5 M	$ 3.4	1.49 %	$ 8.18 B	Australia
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
AstraZeneca PLC AZN	40.9 B	$ 90.34	-1.28 %	$ 96.9 B	Britain
Amphastar Pharmaceuticals AMPH	732 M	$ 25.76	0.19 %	$ 1.25 B	USA
Anika Therapeutics ANIK	271 M	$ 9.53	-1.19 %	$ 140 M	USA
Aytu BioScience AYTU	124 M	$ 2.33	2.3 %	$ 14.6 M	USA
Arena Pharmaceuticals ARNA	785 M	-	-6.81 %	$ 3.04 B	USA
Avenue Therapeutics ATXI	1.86 M	-	-52.27 %	$ 4.45 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Axon Enterprise AXON	2.33 B	$ 586.28	3.15 %	$ 44.4 B	USA
Biogen BIIB	16.7 B	$ 173.03	-2.55 %	$ 25.2 B	USA
Can-Fite BioPharma Ltd. CANF	20.3 M	$ 0.29	-5.01 %	$ 631 M	Israel
Brickell Biotech BBI	11.6 M	-	-5.38 %	$ 6.06 M	USA
Benitec Biopharma BNTC	97.3 M	$ 12.91	0.78 %	$ 531 M	USA
BioNTech SE BNTX	19.4 B	$ 95.9	0.17 %	$ 27.2 B	Germany
Biohaven Pharmaceutical Holding Company Ltd. BHVN	-683 M	$ 11.55	8.86 %	$ 747 M	USA
Enochian Biosciences ENOB	-21.3 M	-	-	$ 40.5 M	USA
Catalyst Biosciences CBIO	78.5 M	$ 15.32	5.73 %	$ 1.01 B	USA
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
BeiGene, Ltd. BGNE	3.33 B	-	0.49 %	$ 251 B	Cayman-islands
Cerus Corporation CERS	56.9 M	$ 2.14	13.23 %	$ 395 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Burford Capital Limited BUR	1.66 B	$ 9.15	-0.44 %	$ 1.47 B	Britain
Berkeley Lights BLI	142 M	-	-7.31 %	$ 87 M	USA
bluebird bio BLUE	195 M	-	-	$ 546 M	USA
Cellectar Biosciences CLRB	-13.8 M	$ 3.81	-5.35 %	$ 46.6 M	USA
Bristol-Myers Squibb Company BMY	16.4 B	$ 51.05	-0.32 %	$ 103 B	USA
Abeona Therapeutics ABEO	14.8 M	$ 5.5	0.46 %	$ 118 M	USA
ADiTx Therapeutics ADTX	8.29 M	$ 2.36	-7.29 %	$ 31.1 K	USA
BioXcel Therapeutics BTAI	-93.1 M	$ 2.1	-4.34 %	$ 5.32 M	USA
Coherus BioSciences CHRS	-193 M	$ 1.42	6.77 %	$ 134 M	USA
BioLineRx Ltd. BLRX	13.5 M	$ 3.22	-2.72 %	$ 908 M	Israel
Celldex Therapeutics CLDX	747 M	$ 28.33	0.5 %	$ 1.82 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Baudax Bio BXRX	-24.2 M	-	0.59 %	$ 63 K	USA
Завод ДИОД DIOD	-243 M	-	-	-	Russia